Over the last 7 days, the United States market has risen by 1.8%, contributing to a 10% increase over the past year, with earnings projected to grow by 14% annually in the coming years. In this ...

Highlights,A substantial portion of Neurocrine Biosciences' shares is currently held by institutional entities.,Avantax ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday.

Of the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...

US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today presented new data from the long-term, ...

Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...

At least three new startups have already been launched out of the fund: U.K.-based Forth Therapeutics, French biotech ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell. ...

Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...

In this article, we will be taking a look at the 15 best biotech stocks to buy according to billionaires. Although biotech ...